Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, ...

Bio-Techne Corp. closed 7.97% below its 52-week high of $85.57, which the company reached on May 15th.

Shares of Bio-Techne Co. (NASDAQ:TECH – Get Free Report) have received a consensus recommendation of “Moderate Buy” from the ...

Bio-Techne Corp. closed $10.84 below its 52-week high ($85.57), which the company achieved on May 15th.

Citigroup has recently reduced BIO-TECHNE Corp (TECH) stock to Neutral rating, as announced on May 22, 2024, according to Finviz. Earlier, on February 8, 2024, Scotiabank had initiated the stock to ...

Bio-Techne Corporation TECH recently announced the launch of a new line of designer proteins engineered using advanced ...

Bio-Techne Corp. (TECH), a life sciences company, announced Tuesday that it has won a second claim of reverse engineering by Miltenyi ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released on January 10, Conor McNamara from RBC Capital maintained a Hold rating on Bio-Techne (TECH – Research Report), with a ...

We’re sorry, we are currently experiencing some issues, please try again later. Our team is working diligently to resolve the issue. Thank you for your patience and ...

Minneapolis, Minnesota-based Bio-Techne Corporation (TECH) develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets.

MINNEAPOLIS, Jan. 7, 2025 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it prevailed on another claim that Miltenyi Biotec B.V. & Co. KG commercialized antibodies ...